Masashi Koto1, Yusuke Demizu2, Jun-Ichi Saitoh3, Hiroaki Suefuji4, Hiroshi Tsuji5, Tomoaki Okimoto2, Tatsuya Ohno3, Yoshiyuki Shioyama4, Hiroaki Ikawa5, Kenji Nemoto6, Takashi Nakano3, Tadashi Kamada5. 1. Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan. Electronic address: koto.masashi@qst.go.jp. 2. Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan. 3. Gunma University Heavy Ion Medical Center, Maebashi, Japan. 4. Ion Beam Therapy Center, SAGA-HIMAT Foundation, Tosu, Japan. 5. Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan. 6. Department of Radiation Oncology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Abstract
PURPOSE: To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN). METHODS AND MATERIALS: Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had naïve tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48%), adenoid cystic carcinoma (n = 122, 27%), squamous cell carcinoma (n = 31, 7%), olfactory neuroblastoma (n = 30, 7%), adenocarcinoma (n = 21, 5%), and other types (n = 33, 7%). Of the 458 patients, 300 (66%) had T4 tumors. All patients received definitive C-ion RT. RESULTS: The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6% and 84.1%, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0% for mucosal melanoma, 96.8% for adenoid cystic carcinoma, 70.0% for squamous cell carcinoma, 96.7% for olfactory neuroblastoma, and 89.7% for adenocarcinoma. Regarding late toxicities, 17% of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common. CONCLUSION: The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors.
PURPOSE: To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN). METHODS AND MATERIALS: Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had naïve tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48%), adenoid cystic carcinoma (n = 122, 27%), squamous cell carcinoma (n = 31, 7%), olfactory neuroblastoma (n = 30, 7%), adenocarcinoma (n = 21, 5%), and other types (n = 33, 7%). Of the 458 patients, 300 (66%) had T4 tumors. All patients received definitive C-ion RT. RESULTS: The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6% and 84.1%, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0% for mucosal melanoma, 96.8% for adenoid cystic carcinoma, 70.0% for squamous cell carcinoma, 96.7% for olfactory neuroblastoma, and 89.7% for adenocarcinoma. Regarding late toxicities, 17% of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common. CONCLUSION: The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors.
Authors: J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti Journal: J Neurooncol Date: 2020-08-12 Impact factor: 4.130
Authors: Sati Akbaba; Dina Ahmed; Andreas Mock; Thomas Held; Suzan Bahadir; Kristin Lang; Mustafa Syed; Juliane Hoerner-Rieber; Tobias Forster; Philippe Federspil; Klaus Herfarth; Peter Plinkert; Juergen Debus; Sebastian Adeberg Journal: Cancers (Basel) Date: 2019-11-01 Impact factor: 6.639
Authors: Sara Ronchi; Barbara Vischioni; Maria Bonora; Amelia Barcellini; Laura D Locati; Paolo Castelnuovo; Piero Nicolai; Cesare Piazza; Mohssen Ansarin; Marco Benazzo; Ester Orlandi Journal: Oral Oncol Date: 2020-05-14 Impact factor: 5.337
Authors: Piero Fossati; Ana Perpar; Markus Stock; Petra Georg; Antonio Carlino; Joanna Gora; Giovanna Martino; Eugen B Hug Journal: Int J Part Ther Date: 2021-06-25